Ras oncogenes: split personalities.

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell (2009) 8.64

RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer (2011) 6.45

Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat Biotechnol (2009) 5.41

Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev (2011) 5.02

Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res (2009) 3.66

Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer (2010) 3.59

Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature (2014) 3.34

In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. Proc Natl Acad Sci U S A (2013) 3.10

Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci U S A (2011) 2.71

RNAi screens in mice identify physiological regulators of oncogenic growth. Nature (2013) 2.46

Therapeutic strategies for targeting ras proteins. Genes Cancer (2011) 2.45

A genome-wide short hairpin RNA screening of jurkat T-cells for human proteins contributing to productive HIV-1 replication. J Biol Chem (2009) 2.40

c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell (2011) 2.28

Characterization of the interface between normal and transformed epithelial cells. Nat Cell Biol (2009) 2.21

Inhibition of Ras for cancer treatment: the search continues. Future Med Chem (2011) 2.14

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. PLoS One (2016) 2.08

Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol (2010) 2.05

Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov (2011) 2.02

Role and regulation of autophagy in cancer. Biochim Biophys Acta (2009) 2.00

Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res (2012) 1.95

KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci (2014) 1.85

Site-specific monoubiquitination activates Ras by impeding GTPase-activating protein function. Nat Struct Mol Biol (2012) 1.76

The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell (2013) 1.75

Involvement of autophagy in oncogenic K-Ras-induced malignant cell transformation. J Biol Chem (2011) 1.74

ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1). J Biol Chem (2010) 1.74

A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Sci Transl Med (2011) 1.72

A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat Genet (2009) 1.71

Ras conformational switching: simulating nucleotide-dependent conformational transitions with accelerated molecular dynamics. PLoS Comput Biol (2009) 1.67

Molecular biology of lung cancer. J Thorac Dis (2013) 1.67

Ras-mediated activation of the TORC2-PKB pathway is critical for chemotaxis. J Cell Biol (2010) 1.64

Roles for KRAS in pancreatic tumor development and progression. Gastroenterology (2013) 1.61

β₁Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. J Clin Invest (2012) 1.56

Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann N Y Acad Sci (2010) 1.54

Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am J Hum Genet (2010) 1.53

Ras/MAPK signaling from endomembranes. Mol Oncol (2009) 1.51

The Ras protein superfamily: evolutionary tree and role of conserved amino acids. J Cell Biol (2012) 1.50

Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. Genes Chromosomes Cancer (2010) 1.50

Evolution of the Ras-like small GTPases and their regulators. Small GTPases (2011) 1.48

Molecular biology of lung cancer: clinical implications. Clin Chest Med (2011) 1.47

Negative regulation of mTOR activation by diacylglycerol kinases. Blood (2011) 1.46

Rational design of small molecule inhibitors targeting the Ras GEF, SOS1. Chem Biol (2014) 1.45

Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease. Oncogene (2013) 1.44

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncol (2011) 1.43

Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors. Sci Signal (2011) 1.43

Large conformational changes in proteins: signaling and other functions. Curr Opin Struct Biol (2010) 1.38

Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation. Proc Natl Acad Sci U S A (2009) 1.36

When ubiquitination meets phosphorylation: a systems biology perspective of EGFR/MAPK signalling. Cell Commun Signal (2013) 1.36

ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res (2011) 1.34

Ras acylation, compartmentalization and signaling nanoclusters (Review). Mol Membr Biol (2008) 1.33

The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery. Genes Cancer (2011) 1.32

Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15. Genes Dev (2013) 1.30

Functional specificity of ras isoforms: so similar but so different. Genes Cancer (2011) 1.30

MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer (2015) 1.27

Direct reprogramming by oncogenic Ras and Myc. Proc Natl Acad Sci U S A (2013) 1.26

Organization, dynamics, and segregation of Ras nanoclusters in membrane domains. Proc Natl Acad Sci U S A (2012) 1.25

Oncogenic K-Ras requires activation for enhanced activity. Oncogene (2013) 1.24

A novel role for copper in Ras/mitogen-activated protein kinase signaling. Mol Cell Biol (2012) 1.24

Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration. Mol Carcinog (2010) 1.24

Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders. Hum Mutat (2010) 1.24

H-Ras forms dimers on membrane surfaces via a protein-protein interface. Proc Natl Acad Sci U S A (2014) 1.23

Cooperative activation of PI3K by Ras and Rho family small GTPases. Mol Cell (2012) 1.23

Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice. Clin Cancer Res (2011) 1.23

RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers. J Clin Endocrinol Metab (2013) 1.22

Analysis of binding site hot spots on the surface of Ras GTPase. J Mol Biol (2011) 1.22

IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR. Oncogene (2011) 1.21

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. Front Oncol (2014) 1.20

Novel allosteric sites on Ras for lead generation. PLoS One (2011) 1.20

Noonan syndrome gain-of-function mutations in NRAS cause zebrafish gastrulation defects. Dis Model Mech (2011) 1.18

Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J (2011) 1.17

Mst1 promotes cardiac myocyte apoptosis through phosphorylation and inhibition of Bcl-xL. Mol Cell (2014) 1.16

A microRNA contribution to aberrant Ras activation in gastric cancer. Am J Transl Res (2011) 1.14

The secret life of kinases: functions beyond catalysis. Cell Commun Signal (2011) 1.13

A high level of liver-specific expression of oncogenic Kras(V12) drives robust liver tumorigenesis in transgenic zebrafish. Dis Model Mech (2011) 1.13

SAG/RBX2/ROC2 E3 ubiquitin ligase is essential for vascular and neural development by targeting NF1 for degradation. Dev Cell (2011) 1.13

Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. PLoS Genet (2010) 1.12

A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype. Elife (2014) 1.12

Utilization of genomic signatures to identify phenotype-specific drugs. PLoS One (2009) 1.12

A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer. Clin Cancer Res (2014) 1.11

Compartmentalized Ras proteins transform NIH 3T3 cells with different efficiencies. Mol Cell Biol (2010) 1.10

PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha. J Clin Invest (2010) 1.09

Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras. Blood (2011) 1.08

Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway. Proc Natl Acad Sci U S A (2015) 1.08

Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. Curr Cancer Drug Targets (2010) 1.07

GTP-Dependent K-Ras Dimerization. Structure (2015) 1.07

STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci U S A (2012) 1.06

The distinct conformational dynamics of K-Ras and H-Ras A59G. PLoS Comput Biol (2010) 1.06

Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway. Oncogene (2011) 1.06

Structural basis of GDP release and gating in G protein coupled Fe2+ transport. EMBO J (2009) 1.05

Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators. J Med Chem (2013) 1.04

Canonical RTK-Ras-ERK signaling and related alternative pathways. WormBook (2013) 1.03

Tumor suppression and promotion by autophagy. Biomed Res Int (2014) 1.02

miR-146a promotes the initiation and progression of melanoma by activating Notch signaling. Elife (2014) 1.02

Regulation of RAS oncogenicity by acetylation. Proc Natl Acad Sci U S A (2012) 1.02

Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. J Gastroenterol (2011) 1.02

Potassium-activated GTPase reaction in the G Protein-coupled ferrous iron transporter B. J Biol Chem (2010) 1.01

The c-Jun NH2-terminal kinase 2 plays a dominant role in human epidermal neoplasia. Cancer Res (2010) 1.00

Human β-cell proliferation and intracellular signaling: part 3. Diabetes (2015) 1.00

Cten is targeted by Kras signalling to regulate cell motility in the colon and pancreas. PLoS One (2011) 0.98

MEK targeting in N-RAS mutated metastatic melanoma. Mol Cancer (2014) 0.98

Ras1(CA) overexpression in the posterior silk gland improves silk yield. Cell Res (2011) 0.98

Functional rafts in cell membranes. Nature (1997) 38.89

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell (1997) 29.13

G proteins: transducers of receptor-generated signals. Annu Rev Biochem (1987) 27.41

Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature (1983) 19.76

Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell (1993) 16.91

Creation of human tumour cells with defined genetic elements. Nature (1999) 16.47

Mechanism of activation of a human oncogene. Nature (1982) 12.09

A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature (1982) 11.92

Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture. Nature (1983) 11.61

Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue. Nature (1983) 10.64

Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature (2001) 10.56

Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature (1994) 10.34

DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature (1976) 9.81

The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science (1997) 9.21

Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science (1990) 8.91

Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (2004) 8.16

A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell (1990) 8.10

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med (1999) 7.97

A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science (1987) 7.69

Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46

Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature (1993) 7.20

The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature (1993) 7.11

Activation of Raf as a result of recruitment to the plasma membrane. Science (1994) 6.97

Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet (2001) 6.96

Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell (1990) 6.94

Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. Nature (1982) 6.78

Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell (1997) 6.55

Cell-cycle control of c-myc but not c-ras expression is lost following chemical transformation. Cell (1984) 6.53

Comparative biochemical properties of normal and activated human ras p21 protein. Nature (1984) 6.50

Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc Natl Acad Sci U S A (1984) 6.45

Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell (2007) 6.44

Endomembrane trafficking of ras: the CAAX motif targets proteins to the ER and Golgi. Cell (1999) 6.42

Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells. Nature (1985) 6.41

Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling. Nature (1993) 6.38

Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature (1984) 6.21

Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature (1994) 6.16

Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J (1997) 6.14

Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature (1982) 6.09

A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell (1990) 6.08

Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. Science (1993) 6.07

An acylation cycle regulates localization and activity of palmitoylated Ras isoforms. Science (2005) 5.99

ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK. Cell (1992) 5.77

Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. Science (1990) 5.76

Increasing complexity of Ras signaling. Oncogene (1998) 5.71

Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell (1993) 5.66

Cloning of bovine GAP and its interaction with oncogenic ras p21. Nature (1988) 5.56

Analysis of two divergent rat genomic clones homologous to the transforming gene of Harvey murine sarcoma virus. Proc Natl Acad Sci U S A (1981) 5.51

Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci U S A (1982) 5.39

Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation. Nature (1989) 5.38

Structure and activation of the human N-ras gene. Cell (1983) 5.25

Multiple Ras functions can contribute to mammalian cell transformation. Cell (1995) 5.24

The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell (1990) 5.24

Biological and biochemical properties of human rasH genes mutated at codon 61. Cell (1986) 5.05

Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins. Science (1986) 4.99

Ras signalling on the endoplasmic reticulum and the Golgi. Nat Cell Biol (2002) 4.91

Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1. Nature (1993) 4.88

The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell (1990) 4.84

p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci U S A (1989) 4.80

Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Mol Cell Biol (1995) 4.78

The S. cerevisiae CDC25 gene product regulates the RAS/adenylate cyclase pathway. Cell (1987) 4.74

The transforming proteins of Rous sarcoma virus, Harvey sarcoma virus and Abelson virus contain tightly bound lipid. Cell (1982) 4.66

Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature (1993) 4.61

The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity. Nature (1984) 4.61

T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. Nature (1982) 4.54

Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras. Nature (1993) 4.54

The structural basis of the activation of Ras by Sos. Nature (1998) 4.50

Germline KRAS mutations cause Noonan syndrome. Nat Genet (2006) 4.48

The p21 ras C-terminus is required for transformation and membrane association. Nature (1984) 4.43

Guanine nucleotide-binding and autophosphorylating activities associated with the p21src protein of Harvey murine sarcoma virus. Nature (1980) 4.43

GTP-dependent segregation of H-ras from lipid rafts is required for biological activity. Nat Cell Biol (2001) 4.42

Molecular cloning of two types of GAP complementary DNA from human placenta. Science (1988) 4.39

Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem (1999) 4.38

Induction of mammary carcinomas in rats by nitroso-methylurea involves malignant activation of H-ras-1 locus by single point mutations. Nature (1984) 4.38

PDGF induction of tyrosine phosphorylation of GTPase activating protein. Nature (1989) 4.36

PRAK is essential for ras-induced senescence and tumor suppression. Cell (2007) 4.30

Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev (2002) 4.30

Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature (1984) 4.28

Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. EMBO J (1984) 4.28

K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev (1997) 4.24

Reovirus therapy of tumors with activated Ras pathway. Science (1998) 4.15

The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell (1990) 4.12

NF1 tumor suppressor gene function: narrowing the GAP. Cell (2001) 4.11

Activation of extracellular signal-regulated kinase, ERK2, by p21ras oncoprotein. EMBO J (1992) 4.00

Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell (1990) 3.99

Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science (2006) 3.96

Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science (1989) 3.90

Identification of a novel Ras-regulated proapoptotic pathway. Curr Biol (2002) 3.89

Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1. Nature (1983) 3.86

Homologies between signal transducing G proteins and ras gene products. Science (1984) 3.85

Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet (2006) 3.81

PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem Sci (1997) 3.68

PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Mol Cell (2006) 3.66

Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med (2004) 3.55

Molecular cloning of cDNAs encoding a guanine-nucleotide-releasing factor for Ras p21. Nature (1992) 3.48

Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses. Proc Natl Acad Sci U S A (1982) 3.48

Time-resolved X-ray crystallographic study of the conformational change in Ha-Ras p21 protein on GTP hydrolysis. Nature (1990) 3.47

Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev (1994) 3.40

Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science (1997) 3.32

H-ras but not K-ras traffics to the plasma membrane through the exocytic pathway. Mol Cell Biol (2000) 3.24

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem (1997) 3.21

Hallmarks of cancer: the next generation. Cell (2011) 140.01

The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08

The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 32.82

Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell (2004) 31.38

Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature (2007) 21.53

Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 18.53

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20

An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet (2008) 17.67

Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20

Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell (2008) 14.80

A perspective on cancer cell metastasis. Science (2011) 13.31

Retracted A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell (2009) 10.51

Tumor metastasis: molecular insights and evolving paradigms. Cell (2011) 10.34

A progression puzzle. Nature (2002) 9.56

Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 8.07

Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A (2004) 7.96

Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res (2008) 7.91

miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol (2010) 6.67

Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A (2010) 6.15

Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A (2011) 5.53

Modelling the molecular circuitry of cancer. Nat Rev Cancer (2002) 5.43

Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci U S A (2007) 5.24

Cancer stem cells: mirage or reality? Nat Med (2009) 5.20

The signals and pathways activating cellular senescence. Int J Biochem Cell Biol (2004) 5.00

Rules for making human tumor cells. N Engl J Med (2002) 4.84

Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol (2010) 4.80

Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell (2011) 4.79

Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol (2002) 4.77

Slug and Sox9 cooperatively determine the mammary stem cell state. Cell (2012) 4.77

The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet (2005) 4.70

Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle (2006) 4.67

Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell (2007) 4.30

Species- and cell type-specific requirements for cellular transformation. Cancer Cell (2004) 4.25

Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol (2012) 3.98

The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med (2013) 3.96

Exploring a new twist on tumor metastasis. Cancer Res (2006) 3.96

Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell (2008) 3.95

Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene (2002) 3.80

Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell (2008) 3.75

The Spemann organizer gene, Goosecoid, promotes tumor metastasis. Proc Natl Acad Sci U S A (2006) 3.64

Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell (2013) 3.61

Retracted Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell (2003) 3.56

Telomerase maintains telomere structure in normal human cells. Cell (2003) 3.29

Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer (2003) 3.23

Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity. Cancer Res (2007) 3.04

Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A (2010) 3.03

Telomeres: cancer to human aging. Annu Rev Cell Dev Biol (2006) 2.88

Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A (2002) 2.82

Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci U S A (2009) 2.75

Tumor-host interactions: a far-reaching relationship. J Clin Oncol (2010) 2.48

Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia (2010) 2.38

When cells get stressed: an integrative view of cellular senescence. J Clin Invest (2004) 2.37

A mouse model of human breast cancer metastasis to human bone. Cancer Res (2005) 2.24

Adaptation versus selection: the origins of metastatic behavior. Cancer Res (2007) 2.08

Micromanagers of malignancy: role of microRNAs in regulating metastasis. Trends Genet (2008) 2.03

Taking the study of cancer cell survival to a new dimension. Cell (2002) 2.03

Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest (2011) 1.96

Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell (2013) 1.86

IGF-2 is a mediator of prolactin-induced morphogenesis in the breast. Dev Cell (2002) 1.79

Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells? Int J Cancer (2011) 1.79

Erosion of the telomeric single-strand overhang at replicative senescence. Nat Genet (2003) 1.78

Cell plasticity and heterogeneity in cancer. Clin Chem (2012) 1.74

Retracted Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis. Genes Dev (2009) 1.74

MicroRNAs in malignant progression. Cell Cycle (2007) 1.74

Retracted Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. Cancer Res (2010) 1.73

Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov (2012) 1.71

Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res (2007) 1.66

MicroRNAs: Crucial multi-tasking components in the complex circuitry of tumor metastasis. Cell Cycle (2009) 1.63

Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos. Mol Cell Biol (2003) 1.59

miR-31: a crucial overseer of tumor metastasis and other emerging roles. Cell Cycle (2010) 1.51

The outgrowth of micrometastases is enabled by the formation of filopodium-like protrusions. Cancer Discov (2012) 1.45

Continuous elimination of oxidized nucleotides is necessary to prevent rapid onset of cellular senescence. Proc Natl Acad Sci U S A (2008) 1.41

Retracted Activation of miR-31 function in already-established metastases elicits metastatic regression. Genes Dev (2011) 1.40

An integrin-linked machinery of cytoskeletal regulation that enables experimental tumor initiation and metastatic colonization. Cancer Cell (2013) 1.36

Metastatic colonization: settlement, adaptation and propagation of tumor cells in a foreign tissue environment. Semin Cancer Biol (2010) 1.36

Roles for microRNAs in the regulation of cell adhesion molecules. J Cell Sci (2011) 1.25

Heterogeneity of stromal fibroblasts in tumors. Cancer Biol Ther (2007) 1.21

Chemokine networks and breast cancer metastasis. Breast Dis (2007) 1.17

AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment. Cancer Res (2010) 1.17

Coevolution in the tumor microenvironment. Nat Genet (2008) 1.16

Senescence: does it all happen at the ends? Oncogene (2002) 0.98

High efficiency creation of human monoclonal antibody-producing hybridomas. J Immunol Methods (2004) 0.94

Assaying microRNA loss-of-function phenotypes in mammalian cells: emerging tools and their potential therapeutic utility. RNA Biol (2009) 0.90

Of mice and (wo)men: mouse models of breast cancer metastasis to bone. J Bone Miner Res (2010) 0.89

Functional genomics and the breast cancer problem. Cancer Cell (2002) 0.86

Cancer cell of origin: spotlight on luminal progenitors. Cell Stem Cell (2010) 0.83

Filling the mosaic of p53 actions: p53 represses RHAMM expression. Cell Cycle (2008) 0.82

Cancer Biology and Therapy: the road ahead. Cancer Biol Ther (2002) 0.81

Is metastasis predetermined? Mol Oncol (2007) 0.81

Poised with purpose: cell plasticity enhances tumorigenicity. Cell Cycle (2013) 0.81

Metastasis suppression: a role of the Dice(r). Genome Biol (2010) 0.78

Retrospective: Judah Folkman (1933-2008). Science (2008) 0.77

Addendum: A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol (2015) 0.76

Health for life. Your lifestyle, your genes, and cancer. Newsweek (2008) 0.75

All You Need Is Mentorship. Cell (2016) 0.75